ArriVent is a clinical stage drug development company in-licensing mature, de-risked assets from Asia with first-in-class or best-in-class potential in the US/EU.

Arrivent’s experienced and well-connected management team is capitalizing on the emergence of high-quality, clinically de-risked drugs developed in China and other geographies that lack the internal regulatory, commercial, or financial backing for clinical development and launch in the US and EU markets. Arrivent’s lead asset is a Ph3 ready best-in-class EGFR inhibitor for non-small cell lung cancer with the potential to land and expand the ~$2B US market into currently unaddressed EGFR mutants. Additional in-licensing opportunities at attractive terms offer multiple additional pathways to value creation.